ストックスクリーナーアプリを入手
39.73
2.99%
1.155
アフターアワーズ：
39.72
-0.005
-0.01%
前日終値:
$38.57
開ける：
$39.16
24時間の取引高:
809.74K
Relative Volume:
2.26
時価総額：
$1.90B
収益：
-
当期純損益:
$-107.28M
株価収益率:
-15.26
EPS:
-2.6031
ネットキャッシュフロー:
$-80.71M
1週間 パフォーマンス:
-4.67%
1か月 パフォーマンス:
+10.04%
6か月 パフォーマンス:
+31.89%
1年 パフォーマンス:
+229.94%
1日の値動き範囲:
$38.50
$42.86
1週間の範囲:
$38.50
$42.86
52週間の値動き範囲:
$11.91
$43.76
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Compare RAPP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
39.73 | 1.84B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Strong Buy |
| 2026-02-02 | 開始されました | Wells Fargo | Overweight |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-16 | 開始されました | Truist | Buy |
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
すべてを表示
Rapport Therapeutics Inc (RAPP) 最新ニュース
How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story - simplywall.st
RAPPRapport Therapeutics Inc Short Interest - Finviz
Rapport Therapeutics Hits New 52-Week High of $43.65 - MarketsMojo
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap - GuruFocus
Understanding the Setup: (RAPP) and Scalable Risk - Stock Traders Daily
Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades - Stock Titan
Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans - Stock Titan
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com - Investing.com Nigeria
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2500 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP) - TradingView
RAPP Forecast — Price Target — Prediction for 2027 - TradingView
RAPP Initiated Coverage by Leerink Partners -- Rating set to Out - GuruFocus
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target - marketscreener.com
Leerink initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
The Technical Signals Behind (RAPP) That Institutions Follow - Stock Traders Daily
Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rapport Therapeutics Inc (RAPP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rapport Therapeutics Inc (RAPP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rapport Therapeutics Inc (RAPP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rapport Therapeutics Inc (RAPP) Institutional Confidence - TradingKey
Is Rapport Therapeutics (RAPP) a Good Stock to Buy? - HarianBasis.co
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? - Insider Monkey
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says - BioPharma Dive
Rapport Therapeutics (RAPP) director receives 15,200 stock options grant - Stock Titan
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity - Stock Titan
Rapport Therapeutics (RAPP) director receives 15,200-share stock option grant - Stock Titan
Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21 - Stock Titan
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting - TipRanks
Rapport Therapeutics (RAPP) holders elect Class II board, ratify PwC - Stock Titan
Goldman Sachs Group Inc. Buys 579,903 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Precision Trading with Rapport Therapeutics Inc. (RAPP) Risk Zones - Stock Traders Daily
Rapport Therapeutics (RAPP) Edges Higher Amid Tight Trading RangePut Flow Alert - newsline.com
Rapport Therapeutics (RAPP) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? - Yahoo Finance
Wall Street Firms Raise Rapport Therapeutics Price Targets - sekbernews.id
BTIG and Truist Raise Price Targets for Rapport Therapeutics - HarianBasis.co
BTIG Raises its Price Target on Rapport Therapeutics (RAPP) - Insider Monkey
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy - TipRanks
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
Number of shareholders of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data - Investing.com
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) 財務データ
収益
当期純利益
現金流量
EPS
Rapport Therapeutics Inc (RAPP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Jun 29 '26 |
Sale |
39.83 |
8,220 |
327,398 |
548,027 |
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):